Pls RT: Are you studying the multifaceted MAPK pathway? We would love to hear about your exciting research!
Abstract Deadline 👉16.12.2024 for the #virtualmeeting on "Drugging and regulating the #MAPKpathway"
organised with @EACRnews with @Boehringer https://t.co/hiyRqSB4En
I am excited for the next three days of @theNCI's RAS Initiative Symposium 2024. Today, @NCIDirector Rathmell and AACR Past President Frank McCormick kicked off this important meeting aimed at mobilizing the cancer research community to target RAS-driven cancers.
Excited to co-organize the virtual @EACRnews@Boehringer Conference: Drugging & Regulating the MAP Kinase Pathway! Submit an abstract or join us. Please RT and share with others.
Details & registration:
https://t.co/KmKFU3xpcz
📣 Out now! First results of the 2024 ERC Proof of Concept call.
100 grants – each worth €150,000 – will help ERC grantees to bridge the gap between the discoveries stemming from their frontier research and their practical application.
More 👉 https://t.co/wcBn2eYMY0
EACR-@Mark Foundation Postdoctoral Fellowships are awarded for a period of three years and support excellent postdoctoral researchers in laboratories throughout Europe. Is that you? 👀
Apply by 21 August: https://t.co/o0qlBiCxhn
There are just a few more days left to register for our upcoming Early-Career Researchers' Conference, happening online 25-26 June!
👉 Don't miss the 12 June deadline: https://t.co/fnQSypBNxy
Stunning results from @CanaudLab who just presented their case study that led to an FDA-approved drug. Thanks @unito for organizing it! #research#24May
There's not long left to wait until the EACR Congress comes to the Netherlands in June! ☀️
Don't miss the opportunity to take advantage of our discounted early registration rate to attend, available until 29 April.
https://t.co/dYUl2wD7aL
Just published with the #AACR24 presentation in Attacking #KRAS Beyond G12C:
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers, by Jingjing Jiang, Zhengping Wang, Mallika Singh et al.
https://t.co/CkAxQMGNRh
#RevolutionMedicines
@BiagioRicciutMD from @DanaFarber is presenting today at #AACR2024 section 41 poster 18 new data on wild type KRAS amplification as a de novo oncogenic driver in NSCLC. Terrific work done in collaboration with @AmbrogioLab. @DrMarkAwad@KRASKickers
Out in @Nature concurrent with #AACR24
Two papers on biochemistry and preclinical characterization of Revolution Medicines’ RAS(ON) multiRAS inhibitor, with a focus on #PancreaticCancer@KenOliveLab@BenStanger01@derlabunc
https://t.co/Ptzrxtj39x
https://t.co/k5Q2buC8h0